CD33 and ovarian carcinoma: Importantly, analogous treatment with scFvFITC:sFasL also markedly triggered apoptosis in 6 out of 7 primary patient-derived ovarian cancer samples when pretargeted with anti-CD44-FITC, but not with anti-CD33-FITC (4 out of 5) (Fig. 4D).